Document Type: Original Research


1 Department of Pathology,Yas Hospital, Tehran University of Medical Sciences,Tehran, Iran

2 Department of Pathology, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran, Iran

3 Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran


Background & Objective: Endometrial carcinoma (EC) has been traditionally classified into two distinct categories of low-grade and high-grade. Type I (low grade) EC, which constitutes the majority of cases, is linked to estrogen-related molecular pathways. But type II (high-grade) EC accounts for 10-20% of cases and behaves in an aggressive way. Pathologic and biological features of type II EC have not been fully elucidated yet. Several investigations have demonstrated HER2/neu expression and amplification in type II EC, especially papillary serous carcinoma (PSC).This study assessed HER2/neu expression in high-grade EC as well as its association with other clinical and histopathological prognostic factors.
Methods: In this cross-sectional study, we performed HER2/neu immunohistochemical (IHC) staining in 37 high-grade EC cases with histological diagnostic categories of PSC (n=23), clear cell carcinoma (CCC) (n=9), and carcinosarcoma with high-grade carcinomatous component (PSC, CCC, grade 3 endometrioid carcinoma, or unclassified high-grade adenocarcinoma) (n=5). All patients were followed for 2-9 years in order to evaluate their disease-free survival (DFS) and overall survival (OS) during study period (2005-2014).
Results: HER2/neu IHC staining was positive in 12 patients (32.4%) including 8/23 (34.8%) PSC, 2/9 (22.2%) CCC, and 2/5 (40%) carcinosarcoma cases. There was no statistically significant difference between HER2/neu expression and DFS or OS of the patients (P>0.05).
Conclusion: We observed that HER2/neu is expressed in one-third of high-grade ECs. This ancillary test is supportive in follow-up of patients with high-grade ECs.


Main Subjects

  1. Togami S, Sasajima Y, Oi T, Ishikawa M, Onda T, Ikeda S, et al. Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. Cancer Sci. 2012;103(5):926-32. [DOI:10.1111 /j.1349-7006.2012.02240.x] [PMID]
  2. Pathiraja P, Dhar S, Haldar K. Serous endometrial intraepithelial carcinoma: a case series and literature review. Cancer Manag Res. 2013;5:117-22. [DOI:10.2147 /CMAR.S45141] [PMID] [PMCID]
  3. Kim HJ, Kim TJ, Lee YY, Choi CH, Lee JW, Bae DS, et al. A comparison of uterine papillary serous, clear cell carcinomas, and grade 3 endometrioid corpus cancers using 2009 FIGO staging system. J Gynecol Oncol. 2013;24(2):120-7. [DOI:10.3802/jgo.2013.24.2.120] [PMID] [PMCID]
  4. Talwar S, Cohen S. Her-2 targeting in uterine papillary serous carcinoma. Gynecol Oncol Case Rep. 2012;2(3):94-6. [DOI:10.1016/j.gynor.2012.05.003] [PMID] [PMCID]
  5. Rossi ED, Bizzarro T, Monterossi G, Inzani F, Fanfani F, Scambia G, et al. Clinicopathological analysis of mixed endometrial carcinomas: clinical relevance of different neoplastic components. Hum Pathol. 2017;62:99-107. [DOI:10.1016/j.humpath.2016.12.015] [PMID]
  6. Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, et al. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. Int J Gynecol Pathol. 2019;38 Suppl 1:S40-S63. [DOI:10.1097/PGP.0000000000000491] [PMID] [PMCID]
  7. Gatius S, Matias-Guiu X. Practical issues in the diagnosis of serous carcinoma of the endometrium. Mod Pathol. 2016;29 Suppl 1:S45-58. [DOI:10.1038/modpathol.2015.141] [PMID]
  8. del Carmen MG, Birrer M, Schorge JO. Uterine papillary serous cancer: a review of the literature. Gynecol Oncol. 2012;127(3):651-61. [DOI:10.1016/j.ygyno.2012.09.012] [PMID]
  9. Santin AD, Bellone S, Siegel ER, Palmieri M, Thomas M, Cannon MJ, et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol. 2005;192(3):813-8. [DOI:10.1 016/j.ajog.2004.10.605] [PMID]
  10. Buza N, Roque DM, Santin AD. HER2/neu in Endometrial Cancer: A Promising Therapeutic Target With Diagnostic Challenges. Arch Pathol Lab Med. 2014;138(3):343-50. [DOI:10.5858/arpa.2012-0416-RA] [PMID]
  11. Hayes MP, Ellenson LH. Molecular alterations in uterine serous carcinoma. Gynecol Oncol. 2010;116(2):286-9. [DOI:10.1016/j.ygyno.2009.11.012] [PMID]
  12. English DP, Roque DM, Carrara L, Lopez S, Bellone S, Cocco E, et al. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor. Gynecol Oncol. 2013;131(3):753-8. [DOI:10.1016/j.ygyno.20 13.08.033] [PMID]
  13. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005;104(7):1391-7. [DOI:10.1002/c ncr.21308] [PMID]
  14. Jones NL, Xiu J, Chatterjee-Paer S, Buckley de Meritens A, Burke WM, Tergas AI, et al. Distinct molecular landscapes between endometrioid and nonendometrioid uterine carcinomas. Int J Cancer. 2017;140(6):1396-404. [DOI:10.1 002/ijc.30537] [PMID]
  15. Xiao W, Dong X, Zhao H, Han S, Nie R, Zhang X, et al. Expression of MIF and c-erbB-2 in endometrial cancer. Mol Med Rep. 2016;13(5):3828-34. [DOI:10.38 92/mmr.201 6.4992] [PMID] [PMCID]
  16. Slomovitz BM, Broaddus RR, Burke TW, Sneige N, Soliman PT, Wu W, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;22(15):3126-32. [DOI:10.120 0/JCO.2004 .11.154] [PMID]
  17. Grushko TA, Filiaci VL, Mundt AJ, Ridderstrale K, Olopade OI, Fleming GF, et al. An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008;108(1):3-9. [DOI:10.1016 /j.ygyno.20 07.09.007] [PMID] [PMCID]
  18. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol. 2006;24(15):2376-85. [DOI:10.1200/JCO.2005.03.4827] [PMID]